Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Razi Cov Pars versus Sinopharm COVID-19 vaccine phase 3 comparison
IRCT20201214049709N3Phase 3Completed
- Sponsor
- Razi Vaccine and Serum Research Institute
- Start
- Sep 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of BBIBP-CorV in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Razi Vaccine and Serum Research Institute. Primary endpoints: PCR-confirmed COVID-19 occurrence, Moderate or severe COVID-19 or death and 4 more. Started Sep 2021; status: completed.
02
Drugs
BBIBP-CorV
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20201214049709N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201214049709N3.